Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Evofem Biosciences, Inc. (EVFM)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 38.7% | 25.7% | 26.2% | 28.6% | 32.5% | 40.5% | 49.2% | 50.6% |
| Gross profit | 61.3% | 74.3% | 73.8% | 71.4% | 67.5% | 59.5% | 50.8% | 49.4% |
| Sales and marketing | 168.7% | 190.8% | 261.0% | 305.9% | 516.4% | 837.0% | 1372.5% | 2316.1% |
| Research and development | 52.9% | 82.5% | 148.7% | 158.2% | 228.0% | 318.3% | 401.9% | 628.2% |
| General and administrative | 121.1% | 120.5% | 163.7% | 148.6% | 184.7% | 228.6% | 299.7% | 517.7% |
| EBITDA | -275.1% | -314.1% | -493.6% | -536.1% | -854.8% | -1314.9% | -2010.9% | -3394.8% |
| Depreciation | 6.2% | 5.4% | 6.0% | 5.2% | 6.9% | 9.6% | 12.4% | 17.7% |
| EBIT | -281.3% | -319.5% | -499.6% | -541.3% | -861.7% | -1324.5% | -2023.3% | -3412.5% |
| Pre-tax income | 474.3% | -256.2% | -455.3% | -592.7% | -1820.9% | -1676.1% | -2488.8% | -4011.2% |
| Income taxes | 0.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% |
| Net income | 452.9% | -263.1% | -463.3% | -589.0% | -1816.0% | -1686.2% | -2501.7% | -4011.5% |
|